Promethazine

T-Cell Non-Hodgkin Lymphoma

Beijing GoBroad HospitalSmall moleculePhase 1/2Active

CC

47/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 33/ 100
Competitive Position: 89/ 100

Competitive context

6 Active assets in the T-Cell Non-Hodgkin Lymphoma cohort.

Asset / Sponsor	Phase	Rating
Fludarabine Beijing GoBroad Hospital	Phase 3	BB
Anti-Thymoglobulin, Rabbit Stanford University	Phase 2	BB
CYCLOSPORIN A Robert Lowsky	Phase 2	B
FILGRASTIM Dana-Farber Cancer Institute	Phase 2	B
Ipilimumab M.D. Anderson Cancer Center	Phase 2	B

View all 14 →

Same molecule, other indications

Promethazine is also rated in:

disruptive behavior disorderDormant

BB

Indicative ·

64 / 100

migraine without auraDormant

B

Indicative ·

62 / 100

physiological malfunction arising from mental factorDormant

B

Indicative ·

60 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.